Theratechnologies Inc. to Present at Lazard Capital Markets Conference

MONTREAL, QUEBEC--(Marketwire - November 16, 2009) - Theratechnologies (TSX: TH) announced today that Dr. Andrea Gilpin, Vice President, Investor Relations and Communications, will be presenting an overview of Theratechnologies at the 6th Annual Lazard Capital Markets Healthcare Conference, which will take place at The St. Regis, in New York City. At her presentation on Wednesday, November 18 at 11:30 a.m., Dr. Gilpin will review the operational accomplishments over the last year and discuss Theratechnologies’ strategy and growth opportunities.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the U.S. authorities, Theratechnologies’ growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.